Assessment of the humoral immunity against diphtheria, tetanus, and hepatitis B among children with acute lymphocytic leukemia
Background: Approximately all systemic therapies for childhood affect the immune system. The behavior of the immune system in leukemia patients following chemotherapy is not yet clearly defined. The probability of vaccination failure and the need for revaccination remain challenging for these patients.
Aim: To evaluate the humoral immunity against diphtheria, tetanus, and hepatitis B in children with acute lymphocytic leukemia (ALL) immediately and 6 months after chemotherapy.
Materials and Methods: In the present prospective cohort study, 21 patients with ALL referred to Mofid Children’s Hospital were studied immediately and 6 months after chemotherapy. Serum samples were collected from patients, and the levels of immunoglobulins (IgG, IgM, IgE, and IgA) antibodies against diphtheria, tetanus, and hepatitis B were determined using specific enzymelinked immunosorbent assay kits. The obtained data were analyzed using Statistical Package for Social Sciences 21 software.
Results: A total of 13 males and 8 females with an average age of 8.6 ± 2.5 years were included in the present study. Six months after chemotherapy, the mean level of IgG, IgM, IgE, and IgA displayed an increase of 563.1 units in IgG, 11 units in IgM, 11.3 units in IgE, and 5 units in IgA levels. Moreover, data revealed that 6 months after chemotherapy, the mean level of IgG antibodies displayed an increase of 7.09, 3.43, and 1.03 units against hepatitis B, diphtheria, and tetanus, respectively. A significant relationship was found between the antibody level against diphtheria and the age group of the patients (p = 0.003).
Conclusion: Humoral immune status was boosted after 6 months of chemotherapy, though all patients had some extent of lasting immune dysfunction. We indicate that survivors of childhood cancer have ongoing humoral immunological defects and may remain at risk for infectious complications after completion of therapy.
Relevance for Patients: The present study indicated that systemic therapies for pediatrics with leukemia affect the immune system. Pediatrics with leukemia may remain at risk for infectious complications after completion of therapy.
[1] Namayandeh SM, Khazaei Z, Najafi ML, Goodarzi E, Moslem A. Global Leukemia in Children 0-14 Statistics 2018, Incidence and Mortality and Human Development Index (HDI): GLOBOCAN Sources and Methods. Asian Pac J Cancer Prev 2020;21:1487. doi: 10.31557/APJCP.2020.21.5.1487
[2] Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. New Engl J Med 2015;373(16):1541-52. doi: 10.1056/NEJMra1400972
[3] Steinherz PG, Brown AE, Gross PA, Braun D, Ghavimi F, Wollner N, et al. Influenza Immunization of Children with Neoplastic Diseases. Cancer 1980;45:750-6. doi: 10.1002/1097-0142(19800215)45:4<750::aidcncr2820450423>3.0.co;2-z
[4] Tavakol M, Delavari S, Salami F, Ansari S, Rasouli SE, Chavoshzadeh Z, et al. Diversity of Malignancies in Patients with Different Types of Inborn Errors of Immunity. Allergy Asthma Clin Immunol 2022;18:106. doi: 10.1186/s13223-022-00747-2
[5] Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, et al. Immune Dysfunctions and Immune-based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Front Immunol 2020;11:594556. doi: 10.3389/fimmu.2020.594556
[6] Nazari S. Mechanical Events in Physiopathology of Idiopathic Pulmonary Emphysema: A Theoretical Analysis. Internet J Thorac Cardiovasc Surg 2002;5: 1-17.
[7] Crawford J, Dale DC, Lyman GH. Chemotherapyinduced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer 2004;100:228-37. doi: 10.1002/cncr.11882
[8] Perkins JL, Harris A, Pozos TC. Immune Dysfunction After Completion of Childhood Leukemia Therapy. J Pediatr Hematol Oncol 2017;39:1-5. doi: 10.1097/MPH.0000000000000697
[9] Layward L, Levinsky RJ, Butler M. Long-term Abnormalities in T and B Lymphocyte Function in Children Following Treatment for Acute Lymphoblastic Leukaemia. Br J Haematol 1981;49:251-8. doi: 10.1111/j.1365-2141.1981.tb07221.x
[10] Caver TE, Slobod KS, Flynn PM, Behm FG, Hudson MM, Turner EV, et al. Profound Abnormality of the B/T Lymphocyte Ratio During Chemotherapy for Pediatric Acute Lymphoblastic Leukemia. Leukemia 1998;12(4):619-22. doi: 10.1038/sj.leu.2400970
[11] Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative Cytotoxicity of Dexamethasone and Prednisolone in Childhood Acute Lymphoblastic Leukemia. JClin Oncol 1996;14(8):2370-6. doi: 10.1200/JCO.1996.14.8.2370
[12] Kung FH, Orgel HA, Wallace WW, Hamburger RN. Antibody Production Following Immunization with Diphtheria and Tetanus Toxoids in Children Receiving Chemotherapy During Remission of Malignant Disease. Pediatrics 1984;74(1):86-9.
[13] Rautonen J, Siimes MA, Lundström U, Pettay O, Lanning M, Salmi TT, et al. Vaccination of Children During Treatment for Leukemia. Acta Pædiatr Scand 1986;75(4):579-85. doi: 10.1111/j.1651-2227.1986.tb10254.x
[14] Alanko S, Salmi TT, Pelliniemi TT. Recovery of Blood T-Cell Subsets after Chemotherapy for Childhood Acute Lymphoblastic Leukemia. Pediatr Hematol Oncol 1994;11:281-92. doi: 10.3109/08880019409141671
[15] Leadman D, Xu Y, Qu S, Zhu Q, editors. Integrative Rare Disease Profile Creation Via NormMap to Advance Rare Disease Research. In: 2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). Las Vegas: IEEE; 2022. doi: 10.1109/BIBM55620.2022.9995172
[16] Lehrnbecher T, Foster C, Vázquez N, Mackall CL, Chanock SJ. Therapy-Induced Alterations in Host Defense in Children Receiving Therapy for Cancer. Journal of Pediatric Hematology Oncology 1997;19(5):399-417. doi: 10.1097/00043426-199709000-00001
[17] Ek T, Mellander L, Andersson B, Abrahamsson J. Immune Reconstitution after Childhood Acute Lymphoblastic Leukemia is Most Severely Affected in the High Risk Group. Pediatr Blood Cancer 2005;44(5):461-8. doi: 10.1002/pbc.20255
[18] Williams AP, Bate J, Brooks R, Chisholm J, Clarke SC, Dixon E, et al. Immune Reconstitution in Children Following Chemotherapy for Acute Leukemia. EJHaem 2020;1(1):142-51. doi: 10.1002/jha2.27
[19] Kosmidis S, Baka M, Bouhoutsou D, Doganis D, Kallergi C, Douladiris N, et al. Longitudinal Assessment of Immunological Status and Rate of Immune Recovery Following Treatment in Children with ALL. Pediatr Blood Cancer 2008;50(3):528-32. doi: 10.1002/pbc.21327
[20] Ibáñez IM, Casas AA, Martinez OC, Aguado JE, Mateos MM. Humoral Immunity in Pediatric Patients with Acute Lymphoblastic Leukaemia. Allergol Immunopathol (Madr) 2003;31(6):303-10. doi: 10.1016/s0301-0546(03)79203-9